Johnson & Johnson said on Tuesday it would buy heart pump maker Abiomed in a $16.6 billion deal, its biggest in nearly six years, as the conglomerate seeks to boost its cardiovascular business.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
